Based on the implication of redox imbalance and ferroptosis in DON pathology 22 , and GAs profile as an Nrf2 activator 27 with anti-ferroptotic potential 28 , we hypothesized that GA protects against DON toxicity by enhancing cellular antioxidant defenses via the Nrf2 pathway, thereby suppressing ferroptosis
The table keeps them in a separate row from the subcutaneous injectable line that names the branded approved products, so compounded options are not presented as approved finished drugs
The reality is more nuanced than th
Regarding the dose increase, some clinics may charge a flat fee regardless of dose increase while others incur additional charges
These numbers come from carefully selected trial populations that excluded many of the profiles described above
Jirapinyo P, Jin DX, Qazi T, Mishra N, Thompson CC